Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03008616
Recruitment Status : Recruiting
First Posted : January 2, 2017
Last Update Posted : February 12, 2019
Sponsor:
Information provided by (Responsible Party):
AMAG Pharmaceuticals, Inc.

Brief Summary:
This study evaluates the use of AMAG-423 (Digoxin Immune Fab) in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.

Condition or disease Intervention/treatment Phase
Severe Preeclampsia Biological: AMAG-423 (digoxin immune fab) Other: Placebo Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia
Actual Study Start Date : April 12, 2017
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Digoxin

Arm Intervention/treatment
Active Comparator: AMAG-423 (digoxin immune fab)
AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
Biological: AMAG-423 (digoxin immune fab)
AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
Other Name: DigiFab

Placebo Comparator: Placebo
Normal saline, 30 minute IV infusion, every 6 hours x 4 days
Other: Placebo
Normal saline, 30 minute IV infusion, every 6 hours x 4 days




Primary Outcome Measures :
  1. Proportion of infants who have severe IVH, NEC, or death by 36 weeks corrected gestational age [ Time Frame: 36 weeks corrected gestational age ]
    Proportion of infants who have severe IVH, NEC, or death by 36 weeks corrected gestational age


Secondary Outcome Measures :
  1. Change from baseline in serum creatinine [ Time Frame: From treatment initiation to 24 hours post first dose ]
    Maternal change from baseline in serum creatinine to 24 hours post first dose

  2. Incidence of pulmonary edema [ Time Frame: From treatment initiation until completion of treatment phase (up to 4 days) ]
    Maternal incidence of pulmonary edema during the treatment period

  3. Proportion of mothers with modified early obstetric warning score >= 3 at 24 hours post first dose [ Time Frame: 24 hours post first dose ]
    Proportion of mothers with modified early obstetric warning score >= 3 at 24 hours post final dose

  4. Delivery latency [ Time Frame: From treatment initiation until delivery ]
    Time from start of treatment until delivery

  5. Anti-hypertensive use during treatment [ Time Frame: From treatment initiation until completion of treatment phase (up to 4 days) ]
    Use of or change in anti-hypertensive use during the treatment period



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Fetal gestational age 23 0/7 to 31 6/7 weeks
  • Treated with expectant management
  • Meets modified ACOG criteria for severe preeclampsia
  • Willing and able to provide written, informed consent

Exclusion Criteria:

  • Decision to deliver within 24 hours has been made
  • Weight > 150 kg
  • Eclampsia
  • Significant antecedent obstetrical problems
  • Clinically significant fetal anomaly or chromosomal abnormalities
  • Chronic renal disease
  • Active hepatic disease, antiphospholipid antibody syndrome, or lupus
  • Unstable medical or psychiatric disorder
  • Need for use of digitalis like products
  • History of anaphylactic allergic reactions
  • Prior use of antibodies/fab fragments from sheep
  • Serum creatinine ≥ 2.0 mg/dL
  • Platelet count < 50,000
  • Pulmonary edema
  • Estimated fetal weight < 5th percentile

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03008616


Contacts
Layout table for location contacts
Contact: Clinical Trial Interest 1-877-233-4781 AMAGCT@druginfo.com

Locations
Layout table for location information
United States, Massachusetts
AMAG Pharmaceuticals, Inc. Recruiting
Waltham, Massachusetts, United States, 02451
Sponsors and Collaborators
AMAG Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: AMAG Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03008616     History of Changes
Other Study ID Numbers: AMAG-423-201
First Posted: January 2, 2017    Key Record Dates
Last Update Posted: February 12, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications
Digoxin
Immunoglobulin Fab Fragments
Anti-Arrhythmia Agents
Cardiotonic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Immunologic Factors